MedPath

Part 3 of a study to evaluate the safety of a single dose of increasing amounts of INO-4885 given via a vein to healthy adult male volunteers

Phase 1
Conditions
o specific health condition being studied - the study is being conducted for safety reasons in healthy male volunteers that do not belong to any target population for the given intervention
No specific health condition being studied - the study is being conducted for safety reasons in healthy male volunteers that do not belong to any target population for the given intervention
Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)
Registration Number
ACTRN12608000412336
Lead Sponsor
Inotek Pharmaceuticals Corporation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
Male
Target Recruitment
12
Inclusion Criteria

Subject's body weight between 65 and 100 kg and Body Mass Index between 18 and 29, inclusive.

Exclusion Criteria

Subject received treatment or participated in a study with any investigational product within 30 days prior to study drug administration; subject used tobacco, alcohol, caffeine, vitamins, or herbal medications within 48 hours prior to study drug administration; subject used or required any prescription medications during the 4 weeks prior to study drug administration

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath